Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) broadly neutralizing antibodies having improved potency and breadth for neutralizing a range of HIV strains. Combinations of broadly neutralizing antibodies can also improve potency over a single antibody composition.
Type:
Grant
Filed:
June 21, 2013
Date of Patent:
January 30, 2018
Assignees:
California Institute of Technology, The Rockefeller University
Inventors:
Ron Diskin, Anthony P. West, Michel C. Nussenzweig, Pamela J. Bjorkman
Abstract: Disclosed herein is a novel recombinant virus vector derived from the attenuated vaccinia virus strain KVAC103. The recombinant virus vector is obtained by inserting an exogenous gene into the KVAC103 and may be used as a safe vaccine delivery vehicle in mammals. Particularly, recombinant viruses obtained by rescuing some of the genes deleted from the parent virus have an enhanced ability to proliferate in cells being cultured, and thus are easily produced. In addition, the recombinant viruses express an increased level of an exogenous antigen, and thus has enhanced immunogenic efficacy. Such recombinant virus vectors may be used in vaccines for preventing diseases, therapeutic vaccines, and molecular biological studies.
Type:
Grant
Filed:
October 15, 2015
Date of Patent:
January 30, 2018
Assignee:
KOREA CENTERS FOR DISEASE CONTROL AND PREVENTION
Abstract: Novel nucleic acids include non-integrative chimeric retroviral genomes including the 5? and 3? long terminal repeat sequences (LTRs) of the caprine lentivirus: the Caprine Arthritis Encephalitis Virus (CAEV) or of another retrovirus not integrating human cells and at least one viral gene of another retrovirus. A vector including such a nucleic acid, an immunogenic or vaccinal composition including the vector or the nucleic acid, as well as their use for treating and/or preventing an infection by a retrovirus or a disease induced by a pathogenic agent are also described.
Type:
Grant
Filed:
September 12, 2012
Date of Patent:
January 30, 2018
Assignee:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S)
Abstract: The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). Also encompassed by the invention are antigen binding proteins that have been humanized. The antigen binding proteins of the invention are useful as a therapeutic agent for treating and/or preventing CMV infections in a patient in need thereof.
Type:
Grant
Filed:
June 9, 2014
Date of Patent:
January 16, 2018
Assignees:
Merck Sharp & Dohme Corp., Board of Regents of the University of Texas System
Abstract: Compositions and methods for the prophylaxis and treatment of human immunodeficiency virus (HIV) infections are disclosed herein. More specifically the present invention discloses describes an autologous dendritic cell (DC) vaccine product derived by culturing a patient's monocytes with granulocyte macrophage colony stimulating factor (GM-CSF) and interferon alpha 2b (IFN-?), loading the DC with a mixture of five lipopeptides of Gag, Nef and Pol HIV antigens, and, optionally activating the DC with lipopolysaccharide (LPS).
Type:
Grant
Filed:
January 21, 2011
Date of Patent:
January 9, 2018
Assignees:
Baylor Research Institute, Agence Nationale de Recherches Sur le Sida Et Les Hepatitis Virales
Inventors:
Jacques F. Banchereau, Monica Montes, Anna Karolina Palucka, Louis M. Sloan, Yves Levy
Abstract: The present invention relates to a method for the in vitro prediction of the probability of a patient developing severe dengue, based on a blood sample, which involves: a) determining the quantity of at least one marker, and b) comparing the quantity with a reference quantity obtained from a group of individuals who have been diagnosed with non-severe dengue, and if the quantity determined in step a) is greater than the reference quantity established in step b), predicting that the patient will develop severe dengue, and also to the use of predictive marker(s) and to a kit to predict the development of severe dengue.
Abstract: This disclosure relates to recombinant bacteria, e.g. L. lactis, expressing heterologous pili containing human immunodeficiency virus (HIV) antigens. In certain embodiments, the recombinant bacteria are administered in combination with other HIV antigens, nucleic acids encoding HIV antigens, recombinant virus encoding HIV antigens, anti-viral agents and/or adjuvants in an effective amount to elicit a mucosal immune response against HIV.
Type:
Grant
Filed:
September 6, 2013
Date of Patent:
January 9, 2018
Assignee:
Emory University
Inventors:
Rama Rao Amara, June R. Scott, Bernard Quigley, Venkateswarlu Chamcha
Abstract: The invention relates to a method for preparing double-layered virus-like particles of rotavirus in vitro. The method comprises the following steps: purifying rotavirus VP6 proteins from a lysis supernatant, and in vitro assembling double-layered virus-like particles consisting of VP2 proteins and VP6 proteins, wherein the proteins and the virus-like particles can be used for preventing or reducing the clinical symptoms caused by rotavirus infection.
Abstract: Disclosed herein are mosaic HIV envelope (Env) polypeptides that can elicit an immune response to HIV (such as cytotoxic T cell (CTL), helper T cell, and/or humoral responses). Also disclosed are sets of the disclosed mosaic Env polypeptides, which include two or more (for example, three) of the polypeptides. Also disclosed herein are methods for treating or inhibiting HIV in a subject including administering one or more of the disclosed immunogenic polypeptides or compositions to a subject infected with HIV or at risk of HIV infection. In some embodiments, the methods include inducing an immune response to HIV in a subject comprising administering to the subject at least one (such as two, three, or more) of the immunogenic polypeptides or at least one (such as two, three, or more) nucleic acids encoding at least one of the immunogenic polypeptides disclosed herein.
Type:
Grant
Filed:
September 30, 2014
Date of Patent:
January 2, 2018
Assignees:
Los Alamos National Security, LLC, Dana-Farber Cancer Institute, Duke University
Inventors:
Bette T. M. Korber, S. Gnanakaran, Simon Perkins, Joseph Sodroski, Barton Haynes
Abstract: Provided are methods for identifying whether a compound inhibits entry of a virus into a cell. The method may include obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus and co-transfecting it into a first cell along with a viral expression vector which lacks a nucleic acid encoding the envelope protein. The method may further include contacting the viral particles produced by the first cell with a second cell to which the virus binds in the absence and presence of the compound and measuring the amount of signal produced by the second cell.
Type:
Grant
Filed:
October 29, 2015
Date of Patent:
December 12, 2017
Assignee:
Monogram Biosciences, Inc.
Inventors:
Douglas Richman, Mary T Wrin, Susan Little, Christos J. Petropoulos, Neil T. Parkin, Jeannette Whitcomb, Wei Huang
Abstract: The present invention relates to the field of detection of viruses, and in particular to detection of viruses using a liquid crystal assay format. In the present invention, virus binding in a detection region is identified by changes in liquid crystal orientation caused by virus binding independent orientation caused by any topography associated with the detection region.
Type:
Grant
Filed:
March 19, 2015
Date of Patent:
November 14, 2017
Assignee:
PLATYPUS TECHNOLOGIES, LLC
Inventors:
Barbara A. Israel, Nicholas Abbott, Christopher Murphy, Karla Anhalt, Syrus Soltaninassab, Doug Hansmann, Bharat Raj Acharya
Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
Type:
Grant
Filed:
November 28, 2011
Date of Patent:
October 10, 2017
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph Blaney, Kathryn Hanley, Ching-Juh Lai
Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
Type:
Grant
Filed:
May 17, 2012
Date of Patent:
October 10, 2017
Assignees:
The Rockefeller University, California Institute of Technology
Inventors:
Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
Abstract: The subject of the invention is a method for purifying the rabies virus, comprising a single ion-exchange chromatography step, said step being cation exchange chromatography according to which: a) the supernatant of a culture of cells infected with this virus is brought into contact with a cation exchange chromatography support comprising a polymethacrylate matrix onto which sulfoisobutyl groups have been grafted such that the rabies virus binds to this support, and; b) the virus is eluted from its support.
Type:
Grant
Filed:
January 9, 2015
Date of Patent:
September 5, 2017
Assignee:
Sanofi Pasteur SA
Inventors:
Virginie Fabre, Celine Rocca, Pierre Riffard, Eric Calvosa
Abstract: The present invention provides, among other things, methods, reagents, and systems for the treatment, detection, analysis, and/or characterization of influenza infections.
Abstract: Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-28 or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed.
Type:
Grant
Filed:
April 28, 2014
Date of Patent:
August 29, 2017
Assignee:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Abstract: The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron microscopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention.
Type:
Grant
Filed:
November 5, 2013
Date of Patent:
August 22, 2017
Assignees:
INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE, CORNELL UNIVERSITY
Inventors:
Michael Caulfield, Albert Cupo, Hansi Dean, Simon Hoffenberg, C. Richter King, P. J. Klasse, Andre Marozsan, John P. Moore, Rogier W. Sanders, Andrew Ward, Ian Wilson, Jean-Philippe Julien
Abstract: Compositions and methods are provided relating to HCV E2 protein and modifications thereto which enhance the immunogenicity of the protein for vaccine development with respect to the generation of a neutralizing immune response.
Type:
Grant
Filed:
September 22, 2014
Date of Patent:
August 15, 2017
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Steven Foung, Zhen-Yong Keck, Thomas R. Fuerst
Abstract: The present invention provides a method for purification of a virus or virus antigen comprising providing a virus preparation and centrifugation of said virus preparation in a gradient of a sugar established by the addition of two or more buffered sugar layers of different concentration. The method leads to higher yields and reduces unwanted aggregation of the virus or virus antigen by increasing the volume of the peak pool.
Type:
Grant
Filed:
January 23, 2015
Date of Patent:
August 15, 2017
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Manfred Reiter, Leopold Grillberger, Wolfgang Mundt, Artur Mitterer, Horst Schafhauser
Abstract: The present invention provides AAV capsid proteins comprising modification of one or a combination of the surface-exposed lysine, serine, threonine and/or tyrosine residues in the VP3 region. Also provided are rAAV virions comprising the AAV capsid proteins of the present invention, as well as nucleic acid molecules and rAAV vectors encoding the AAV capsid proteins of the present invention. Advantageously, the rAAV vectors and virions of the present invention have improved efficiency in transduction of a variety of cells, tissues and organs of interest, when compared to wild-type rAAV vectors and virions.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
August 8, 2017
Assignee:
University of Florida Research Foundation, Inc.
Inventors:
Arun Srivastava, George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-McKenna